Chemistry Platform

Our strengths include structure based design and drug optimization. We employ fragment screening, virtual screening, chemoinformatics, and property predictions to maximize the speed and efficiency of project progression.

Risks are mitigated from the earliest discovery stages by assuring thorough understanding of each chemotypewith respect to factors including clearance, exposure, efflux liabilities, safety, and off-target activities.

We have used these approaches to develop multiple novel series of BRD inhibitors that show high affinity, excellent physicochemical profiles, and high overall druggability.